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Abstract
Purpose Accumulating evidence suggests that not all cancer
chemotherapy patients who receive first-cycle pegfilgrastim
prophylaxis continue to receive it in subsequent cycles and
that these patients may be subsequently at higher risk of fe-
brile neutropenia (FN). Additional evidence from US clinical
practice is warranted.
Methods Data from two US private healthcare claims reposi-
tories were employed. The source population comprised
adults who received Bintermediate-risk^ or Bhigh-risk^ che-
motherapy regimens for solid cancers or non-Hodgkin’s lym-
phoma and first-cycle pegfilgrastim prophylaxis. From the
source population, all patients who did not receive second-
cycle pegfilgrastim prophylaxis ("comparison patients^) were
matched (1:1) to those who received it (Bpegfilgrastim
patients^) based on cancer, regimen, and propensity score.
Odds ratios (OR) for FN—broad and narrow definitions—
during the second chemotherapy cycle were estimated for
comparison patients versus pegfilgrastim patients using gen-
eralized estimating equations.
Results A total of 2245 comparison patients (5.3 % of source
population) were matched to pegfilgrastim patients; cohorts
were well-balanced on baseline characteristics. Second-cycle
FN incidence proportions for comparison and pegfilgrastim
patients were 3.8 versus 2.2 % based on broad definition and
2.6 versus 0.8 % based on narrow definition; corresponding
OR were 1.7 (95 % CI 1.2–2.5, p=0.002) and 3.5 (95 % CI
2.0–6.0, p<0.001). Results were similar within cancer/
regimen-subgroups and were robust when using alternative
methods for confounding adjustment.
Conclusions In this retrospective evaluation of cancer chemo-
therapy patients who received first-cycle pegfilgrastim pro-
phylaxis in US clinical practice, a clinically relevant minority
did not receive second-cycle prophylaxis. Second-cycle FN
odds among this subset were significantly higher than they
were among those who continued prophylaxis.
Keywords Febrile neutropenia . Pegfilgrastim . Neulasta .
Granulocyte colony-stimulating factor
Introduction
Neutropenia is a common side effect of myelosuppressive
chemotherapy that increases the risk of infection. When neu-
tropenic patients develop fever (i.e., febrile neutropenia [FN]),
the cardinal signs of an opportunistic infection typically ne-
cessitate hospitalization for urgent evaluation, ongoing moni-
toring, and administration of intravenous (IV) antibiotics [1,
2]. FN, as well as severe or prolonged neutropenia, can lead to
dose delays, dose reductions, and/or chemotherapy discontin-
uations, interfering with the delivery of optimal treatment and
possibly adversely affecting patient outcomes [1, 3–7].
Clinical practice guidelines recommend prophylaxis with a
colony-stimulating factor (CSF) when FN risk is high (>20%)
based on either chemotherapy regimen risk alone or a combi-
nation of regimen risk and patient risk factors [8]. Among the
CSFs that are commercially available in the USA,
pegfilgrastim is by far the agent most widely used in clinical
practice as, unlike others agents, it requires only a single dose
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in each chemotherapy cycle [9–12]. There is an abundance of
evidence from clinical trials that primary prophylaxis with
pegfilgrastim (i.e., planned administration in the first and all
subsequent chemotherapy cycles) reduces FN risk during the
chemotherapy course. Accumulating evidence from clinical
practice suggests, however, that not all cancer chemotherapy
patients who receive pegfilgrastim prophylaxis in the first cy-
cle (when FN risk is highest) continue to receive it in subse-
quent cycles (when FN risk in any of these cycles is typically
lower than first-cycle FN risk) [9, 13–20].
The impact of abbreviated pegfilgrastim prophylaxis (i.e.,
early discontinuation of pegfilgrastim prophylaxis) on FN risk
was recently evaluated in a randomized open-label multicenter
trial of breast cancer patients with projected FN risk >20 %
receiving tri-weekly polychemotherapy in the Netherlands
[21]. Eligible patients were randomly assigned to either pri-
mary pegfilgrastim prophylaxis throughout all chemotherapy
cycles (Bstandard arm^) or to primary prophylaxis during the
first two cycles only (Bexperimental arm^). Notably, after 167
subjects were enrolled (out of the 230 planned), the random
assignment of subjects was prematurely stopped based on the
recommendation of the Independent Data Monitoring
Committee because of an unexpectedly high FN rate during
the course in the experimental arm (36 vs. 10% in the standard
arm; adjusted odds ratio=5.8 [95 % CI 2.5–13.8]). FN risk in
the experimental arm was highest (24 %) in the first cycle
without prophylaxis (i.e., the third cycle of chemotherapy).
While available literature suggests that the use of abbreviated
CSF prophylaxis schedules—especially those limiting CSF to
the first cycle of chemotherapy—is gaining popularity in clin-
ical practice due to cost concerns, its use, and impact in this
setting has not been formally and thoroughly examined [13,
14, 22]. We thus undertook a study to provide real-world
evidence on the use and potential implications of abbreviated
pegfilgrastim prophylaxis schedules in US clinical practice.
Methods
Study design
A retrospective cohort design and data from two large US
healthcare claims repositories were employed. To minimize
healthy survivor bias and other (e.g., selection) biases that
would likely occur in such an observational study if it were
designed to mimic the above-described trial by Aarts and col-
leagues, the evaluation was limited to receipt or no receipt of
pegfilgrastim prophylaxis during the second chemotherapy
cycle among a cohort of patients who all received first-cycle
pegfilgrastim prophylaxis. A detailed description of study de-
sign and study methods may be found in the online supple-
ment (Online Resource A).
Data source
Data from the two US healthcare claims repositories spanned
January 1, 2006 through December 31, 2013, and were pooled
for analyses. The two study repositories, the Truven Health
Analytics MarketScan® Commercial Claims and Encounters
and Medicare Supplemental and Coordination of Benefits
Databases (BMarketScan Database^), and the IMS
LifeLink™ PharMetrics Plus Health Plan Claims Database
(BLifeLink Database^), comprise medical (i.e., facility and
professional service) and outpatient pharmacy claims from a
large number of participating private US health plans. Formal
approval for this study from an Institutional Review Board
(IRB) was not required because the design was retrospective
in nature, and subjects in the study databases could not be
identified—directly or indirectly—through variables linked
to their claims and/or enrollment records. Use of the study
databases for health services research is fully compliant with
the Health Insurance Portability and Accountability Act
(HIPAA) Privacy Rule and federal guidance on Public
Welfare and the Protection of Human Subjects [23].
Source and study populations
The source population comprised all patients aged ≥18 years
who, from July 2006 to June 2013, received a course of my-
elosuppressive chemotherapy of at least two cycles duration
for a single primary solid tumor or non-Hodgkin’s lymphoma
(NHL). For each patient in the source population, the first
observed course of chemotherapy and the first two cycles of
chemotherapy within that course were characterized. Only
patients who received first-cycle pegfilgrastim prophylaxis
had continuous health benefits for ≥6 months prior to chemo-
therapy, did not have evidence of reactive CSF use or FN in
cycle 1, did not receive prophylaxis with other CSF agents
(filgrastim, sargramostim) or antimicrobials in either cycle 1
or cycle 2, and met all other selection criteria (as described in
the online supplement) that were retained in the source popu-
lation. Prophylactic use of pegfilgrastim was defined as re-
ceipt 1–3 days following completion of myelosuppressive
chemotherapy administration in a given chemotherapy cycle,
which is consistent with the indicated administration schedule
and National Comprehensive Cancer Network (NCCN)
guidelines [8, 9]. Use of pegfilgrastim was identified based
on medical claims with corresponding Healthcare Common
Procedure Coding System (HCPCS) Level II codes (C9119,
S0135, J2505). From the source population, all patients who
did not receive pegfilgrastim prophylaxis in their second cycle
of chemotherapy (Bcomparison patients^) were matched to
those who received it (Bpegfilgrastim patients^).
Matching was implemented for each patient in the source
population who did not receive second-cycle pegfilgrastim
prophylaxis by first identifying all Bcandidate^ patients who
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received second-cycle pegfilgrastim prophylaxis and had the
same cancer type and chemotherapy regimen. From all such
candidates for each patient, the candidate with the closest pro-
pensity score to the comparison patient was selected as the
matched patient using a fixed 1:1 ratio and nearest-neighbor
approach [24]. Propensity scores represent the conditional
probability of assignment to the exposure group and may be
used to control for multiple observed covariates that are asso-
ciated with exposure and outcome [25, 26]. Propensity scores
for receipt of second-cycle pegfilgrastim prophylaxis were
estimated using multivariate logistic regression; independent
variables included all patient, cancer, and treatment character-
istics described below. The study population was limited to
patients who received intermediate/high-risk chemotherapy
regimens for non-metastatic breast cancer, non-metastatic co-
lorectal cancer, non-metastatic lung cancer, or NHL, and for
which the number of patients who discontinued pegfilgrastim
prophylaxis in cycle 2 was ≥100 (Table 1).
FN episodes
FN episodes were ascertained beginning 4 days after comple-
tion of myelosuppressive chemotherapy administration in the
second cycle of chemotherapy and ending on the last day of
that cycle, and were identified using a Bbroad^ definition, as
follows [ 27]. FN episodes requiring inpatient care were iden-
tified based on hospital admissions with a principal or second-
ary diagnosis of neutropenia (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] 288.0), or fever (780.6), or infection (codes in Online
Resource A). FN episodes requiring outpatient care only were
identified based on ambulatory encounters (e.g., those in a
physician’s office, emergency department, or home) with a
diagnosis of neutropenia, or fever, or infection and—on the
same date—a HCPCS Level I (i.e., Current Procedural
Terminology [CPT]) code for IV administration of
antimicrobial therapy. Such encounters that preceded or
followed an FN-related hospitalization during the same cycle
of chemotherapy were not considered as a separate outpatient
episode (i.e., they were classified as part of the episode of FN
requiring inpatient care). An alternative (Bnarrow^) definition
for FN comprising inpatient encounters with a principal or
secondary diagnosis of neutropenia, and outpatient encounters
with a diagnosis of neutropenia and evidence of IVantimicro-
bial therapy, was also evaluated [27].
Patient, cancer, and treatment characteristics
Patient characteristics included many of those listed by the
American Society of Clinical Oncology (ASCO) and NCCN
as important risk factors for FN and thus those that could
confound the estimated relationship between prophylaxis dis-
continuation and FN risk. Patient characteristics were evalu-
ated based on evidence during the period beginning up to
12 months prior to the date of chemotherapy initiation and
ending 3 days after completion of chemotherapy in the second
cycle (unless otherwise noted in the online supplement).
Characteristics included the following: age; sex; presence
of selected chronic comorbidities (cardiovascular disease, di-
abetes, liver disease, lung disease, renal disease, osteoarthritis,
rheumatoid disease, thyroid disorder); body weight/nutritional
status (obesity, underweight, malnutrition); proxies for health
status (hospice/skilled nursing facility [SNF] care) and phys-
ical function (use of hospital bed, supplemental oxygen, walk-
ing aid, wheelchair); use of immunosuppressive therapy; his-
tory of blood disorders (anemia, neutropenia, other), infection,
recent surgery (i.e., ≤90 days prechemotherapy), hospitaliza-
tion (all-cause and FN-related, respectively), chemotherapy,
and radiation therapy; total healthcare expenditures in the
baseline period; presence of metastatic disease; and calendar





lung cancer, or NHL




Non-metastatic breast cancer TC Q3W Q4W
TAC Q3W Q4W
TCH Q3W Q4W
AC and AC-T (Dose Dense) Q2W Q3W/Q4W
Non-metastatic colorectal cancer FOLFOX Q2W Q3W/Q4W
Non-Hodgkin’s lymphoma CHOP Q2W/Q3W Q4W
CHOP-R Q2W/Q3W Q4W
Non-metastatic lung cancer CAR+PAC Q3W Q4W
TC docetaxel+cyclophosphamide, TAC docetaxel+doxorubicin+cyclophosphamide, TCH docetaxel+
carboplatin+trastuzumab, AC and AC-T doxorubicn+cyclophosphamide, with or without subsequent docetaxel
or paclitaxel, FOLFOX folinic acid+fluorouracil+oxaliplatin, CHOP cyclophosphamide+doxorubicin+vincris-
tine+prednisone with rituximab (R), CAR+PAC carboplatin+paclitaxel, PEG pegfilgrastim, Q2W once every
2 weeks, Q3W once every 3 weeks, Q4W once every 4 weeks
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Statistical analyses
The adequacy of the matching procedure in terms of patients’
baseline characteristics was evaluated using standardized dif-
ferences; a value <0.1 was assumed to indicate a negligible
difference in the characteristic between comparison patients
and pegfilgrastim patients [28, 29]. Comparisons of second-
cycle FN odds between comparison patients and pegfilgrastim
patients were evaluated on an overall basis and within cancer-
and regimen-specific subgroups using generalized estimating
equation (GEE) regression models; a binomial distribution
and logistic link function were specified for all GEE models,
and the models were fitted using an exchangeable correlation
structure. GEE models were used to account for the matched-
pairs design; additional covariates were not included in the
models (since groups were well-balanced on their baseline
characteristics).
All statistical tests were two-sided and were performed at a
significance level of α=0.05. Assuming an approximate 50%
increase in second-cycle FN risk among patients not receiving
pegfilgrastim prophylaxis in that cycle (6.4 vs. 4.2 % for those
receiving pegfilgrastim prophylaxis) and assuming further
that the minimum sample size for each group would be at least
2000 (4000 in total), we calculated that the beta (β) for this
evaluation would be <20 % (two-sided α=0.05) and thus the
study should have adequate power (>80 %) to evaluate the
primary objective [13].
The sensitivity of study results to alternative methods for
confounding adjustment (i.e., using all patients qualifying for
inclusion in the source population and multivariate regression)
and alternative methods for propensity-score matching (i.e.,
1:3 ratio and sequential) were evaluated. In multivariate re-
gression analyses, all patients in the source population with a
qualifying cancer-regimen combination were included, and
the second-cycle FN odds ratio for comparison patients versus
pegfilgrastim patients was estimated using a logistic model
including all potential confounders as independent variables.
Results
A total of 68,442 adult patients underwent a course of myelo-
suppressive chemotherapy of at least two cycle duration for a
single primary solid tumor or NHL from July 2006 to
June 2013 and were administered first-cycle pegfilgrastim
prophylaxis; 42,314 (62 %) received one of the intermediate/
high-risk regimens of interest for one of the cancer types of
interest and met all other criteria for inclusion in the source
population. Of these patients, 2245 (5.3 %) were not admin-
istered second-cycle pegfilgrastim prophylaxis (Bcomparison
patients^) and were matched to those who did (Bpegfilgrastim
patients^). A description of the numbers of patients qualifying
for inclusion in the source and study populations may be
found in the online supplement (Online Resource B).
Among matched patients, 78 % had breast cancer (50 %
received docetaxel+cyclophosphamide [TC], 30 % received
doxorubicin+cyclophosphamide with or without subsequent
docetaxel or paclitaxel [AC/AC-T, dose-dense]), 8 % had co-
lorectal cancer (folinic acid+ fluorouracil+oxaliplatin
[FOLFOX]), 8 % had NHL (cyclophosphamide+doxorubi-
cin+vincristine+prednisone with rituximab [R-CHOP]), and
6 % had lung cancer (carboplatin+paclitaxel [CAR+PAC])
(Table 2). With one exception, matched comparison and
pegfilgrastim patients were well-balanced on their baseline
characteristics; only day of pegfilgrastim administration in
cycle 1 was somewhat different between groups (next day
after chemotherapy administration: 78 vs. 82 %, standard dif-
ference=0.1). Characteristics of comparison patients and
pegfilgrastim patients within cancer- and regimen-specific
subgroups were largely comparable and are set forth in the
online supplement.
On an overall basis, second-cycle incidence proportion for
FN (broad definition) among comparison patients was 3.8
versus 2.2 % among pegfilgrastim patients; the corresponding
odds ratio was 1.7 (95 % CI=1.2–2.5, p value=0.002)
(Table 3). Second-cycle incidence proportion for FN based
on the narrow definition was 2.6 versus 0.8 %, and the corre-
sponding odds ratio was 3.5 (95 % CI=2.0–6.0; p value<
0.001). Across subgroups defined on the basis of cancer type
and chemotherapy regimen, results were generally compara-
ble with a few exceptions.
Second-cycle FN odds ratios for comparison patients ver-
sus pegfilgrastim patients, overall and by cancer/regimen
combination, that were estimated using multivariate logistic
regression are presented in Table 3 and were similar to those
from the matched sample analysis. Results from analyses
using an alternative approach to matching were also compa-
rable (online supplement).
Discussion
The results of this study, based on a retrospective cohort
design and two large US healthcare claims repositories,
suggest that an important minority of cancer chemotherapy
patients who receive first-cycle pegfilgrastim prophylaxis
do not receive second-cycle pegfilgrastim prophylaxis in
clinical practice. While our study focused on prophylaxis
discontinuation after the first cycle, the cumulative inci-
dence of prophylaxis discontinuation at any time during
the chemotherapy course was notably higher: Among the
42,314 patients who received pegfilgrastim prophylaxis in
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Table 2 Characteristics of patients who received pegfilgrastim prophylaxis in cycle 1 only and patients who received pegfilgrastim prophylaxis in




Pegfilgrastim in cycles 1 and 2
Matched subjects (n=2245) All subjects (n=40,069)
% or mean (SD) Stand. diff.a (vs. PEG
in cycle 1 only)
% or mean (SD) p value (vs. PEG
in cycle 1 only)
Patient
Age (years)
Mean (SD) 55.2 (10.9) 55.1 (10.7) 0.011 54.6 (10.7) 0.019
Male, % 11.9 12.4 0.015 10.4 0.023
Chronic comorbidities, %
Liver disease 3.3 3.8 0.027 3.0 0.408
Lung disease 5.1 5.4 0.012 3.6 0.000
Renal disease 2.1 1.8 0.022 1.5 0.014
Osteoarthritis 6.4 6.5 0.004 6.6 0.714
Rheumatoid disease 1.0 1.1 0.004 1.0 0.923
Thyroid disorder 12.1 13.1 0.031 11.5 0.410
Body weight and nutritional status, %
Obese 4.5 4.0 0.024 4.3 0.677
Underweight 0.1 0.1 0.000 0.0 0.134
Malnutrition 0.4 0.2 0.039 0.5 0.725
Proxies for health status, %
Hospice care 0.2 0.2 0.000 0.3 0.618
SNF 0.6 0.7 0.011 0.6 0.859
Hospice or SNF 0.8 0.9 0.009 0.8 0.991
Proxies for physical function, %
Use of hospital bed 0.1 0.3 0.038 0.2 0.427
Use of supplemental oxygen 2.6 2.6 0.003 2.5 0.848
Use of walking aid 1.6 1.5 0.004 1.2 0.176
Use of wheel chair 0.3 0.3 0.008 0.3 0.917
Any of above 4.3 4.4 0.004 3.9 0.346
Use of immunosuppressive drugs, % 4.1 3.4 0.033 4.8 0.114
History of other conditions/events, %
Anemia 15.2 15.8 0.015 14.9 0.639
Neutropenia 6.2 6.0 0.007 6.6 0.404
Other blood disorders 6.0 4.9 0.049 6.0 0.991
Infection 35.0 34.8 0.004 32.8 0.030
Recent surgery (prior 90 days) 69.1 69.1 0.001 66.7 0.018
History of hospitalization for any reason 38.2 37.2 0.020 34.9 0.001
History of chemotherapy 0.1 0.0 0.042 0.2 0.422
History of radiation therapy 3.8 4.1 0.016 4.2 0.446
Prechemotherapy expenditures ($),
mean±SD
34,015 (31, 232) 33,855 (27, 606) 0.005 32,989 (25, 395) 0.066
Cancer, primary site, %
Female breast 78.3 78.3 – 81.6 <0.0001
Colon/rectum 7.8 7.8 – 3.2
Lung 6.4 6.4 – 3.4
Non-Hodgkin’s lymphoma 7.5 7.5 – 11.8
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the first cycle, 16 % did not receive it in one or more
subsequent cycles during their course. Notwithstanding
differences in study designs, study populations, and study
methods, this finding is consistent with evidence from the
published literature [13, 14].
More notably, the results of this study also suggest that the
odds of second-cycle FN are significantly higher among this
subset (i.e., those who discontinue prophylaxis in the second
cycle) versus patients who continue to receive prophylaxis.





Pegfilgrastim in cycles 1 and 2
Matched subjects (n=2245) All subjects (n=40,069)
% or mean (SD) Stand. diff.a (vs. PEG
in cycle 1 only)
% or mean (SD) p value (vs. PEG
in cycle 1 only)
Chemotherapy and supportive care
Chemotherapy Regimen, %
Breast cancer
TC 49.5 49.5 – 30.5 <0.0001
TAC 6.3 6.3 – 11.6
AC and AC-T (dose dense) 30.4 30.4 – 45.9
TCH 13.8 13.8 – 12.0
Colorectal cancer
FOLFOX 100.0 100.0 – 100.0 –
Non-Hodgkin’s lymphoma
CHOP 91.1 89.9 – 91.3 0.9380
CHOP-R 8.9 10.1 – 100.0 –
Lung cancer
CAR+PAC 100.0 100.0 – 100.0 –
Number of myelosuppressive drugs, %
1 0.0 0.0 0.000 0.0 <0.001
2 76.7 76.7 0.000 69.0 <0.001
≥3 23.3 23.3 0.000 31.0 <0.001
Year of chemotherapy, %
2006–2008 30.4 31.6 0.026 27.9 <0.001
2009–2010 34.3 33.1 0.025 30.8 <0.001
2011–2013 35.3 35.3 0.001 41.3 <0.001
Day of pegfilgrastim prophylaxis (relative to last day of chemotherapy)
Cycle 1
Day +1 77.8 81.8 0.100 85.7 <0.001
Day +2 12.3 9.6 0.086 7.3 <0.001
Day +3 9.9 8.6 0.046 7.0 <0.001
Cycle 2
Day +1 0.0 82.0 – 86.8 –
Day +2 0.0 10.5 – 7.4 –
Day +3 0.0 7.4 – 5.8 –
PEG pegfilgrastim, SD standard deviation, SNF skilled nursing facility, TC docetaxel+cyclophosphamide, TAC docetaxel+doxorubicin+cyclophos-
phamide, TCH docetaxel+carboplatin+trastuzumab,AC and AC-T doxorubicin+cyclophosphamide, with or without subsequent docetaxel or paclitaxel,
FOLFOX folinic acid+fluorouracil+oxaliplatin, CHOP cyclophosphamide+doxorubicin+vincristine+prednisone with rituximab (R), CAR+PAC
carboplatin+paclitaxel
a Standard difference: values <0.1 assumed to indicate negligible difference
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Table 3 Odds ratios for febrile neutropenia during second cycle of chemotherapy among patients who received pegfilgrastim prophylaxis in cycle 1
only versus patients who received pegfilgrastim prophylaxis in cycle 1 and cycle 2, overall and within cancer/regimen-specific subgroupsa
FN-broad definitionb, inpatient+outpatient FN-narrow definitonc, inpatient+outpatient
n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value
All cancer types
Matched patients
PEG in cycle 1 only (n=2245) 86 (3.8) 1.7 (1.2–2.5) 0.002 58 (2.6) 3.5 (2.0–6.0) <0.001
PEG in cycles 1 and 2—matched (n=2245) 50 (2.2) 17 (0.8)
All patients†
PEG in cycle 1 only (n=2245) 86 (3.8) 2.3 (1.8–2.9) <0.001 58 (2.6) 4.5 (3.3–6.0) <0.001




PEG in cycle 1 only (n=870) 33 (3.8) 2.2 (1.2–4.2) 0.011 27 (3.1) 9.3 (2.8–30.7) <0.001
PEG in cycles 1 and 2—matched (n=870) 15 (1.7) 3 (0.3)
All patients†
PEG in cycle 1 only (n=870) 33 (3.8) 3.0 (2.0–4.5) <0.001 27 (3.1) 10.8 (6.4–18.3) <0.001
PEG in cycles 1 and 2—all (n=9972) 138 (1.4) 32 (03) <0.001
TAC
Matched patients
PEG in cycle 1 only (n=110) 5 (4.5) 2.6 (0.5–13.9) 0.272 5 (4.5) – –
PEG in cycles 1 and 2—matched (n=110) 2 (1.8) 0 (0.0)
All patients†
PEG in cycle 1 only (n=110) 5 (4.5) 2.8 (1.1–7.3) 0.034 5 (4.5) 7.4 (2.6–20.7) <0.001
PEG in cycles 1 and 2—all (n=3801) 74 (1.9) 29 (0.8)
TCH
Matched patients
PEG in cycle 1 only (n=243) 10 (4.1) 3.4 (0.9–12.8) 0.066 6 (2.5) – –
PEG in cycles 1 and 2—matched (n=243) 3 (1.2) 0 (0.0)
All patients†
PEG in cycle 1 only (n=243) 10 (4.1) 3.2 (1.6–6.5) 0.002 6 (2.5) 21.0 (5.4–81.2) <0.001
PEG in cycles 1 and 2—all (n=3904) 55 (1.4) 5 (0.1)
AC and AC-T (dose dense)
Matched patients
PEG in cycle 1 only (n=534) 17 (3.2) 1.0 (0.5–2.0) 1.000 12 (2.2) 1.1 (0.5–2.5) 0.835
PEG in cycles 1 and 2—matched (n=534) 17 (3.2) 11 (2.1)
All patients†
PEG in cycle 1 only (n=534) 17 (3.2) 1.6 (1.0–2.7) 0.054 12 (2.2) 2.0 (1.1–3.6) 0.029
PEG in cycles 1 and 2—all (n=15,005) 289 (1.9) 168 (1.1)
Non-metastatic colorectal cancer-FOLFOX
Matched patients
PEG in cycle 1 only (n=175) 4 (2.3) – – 1 (0.6) – –
PEG in cycles 1 and 2—matched (n=175) 0 (0.0) – – 0 (0.0)
All patients†
PEG in cycle 1 only (n=175) 4 (2.3) 3.3 (0.9–11.7) 0.063 1 (0.6) – –
PEG in cycles 1 and 2—all (n=1297) 13 (1.0) 1 (0.1) – –
Non-Hodgkin’s lymphoma CHOP and CHOP-R
Matched patients
PEG in cycle 1 only (n=169) 11 (6.5) 1.6 (0.6–4.1) 0.320 5 (3.0) 1.7 (0.5–6.0) 0.419
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alternative definition for FN, an alternative matching de-
sign, and all patients qualifying for inclusion in the source
population (with adjustment for confounding via multivar-
iate regression), and are directionally consistent with those
from the aforementioned multicenter trial of breast cancer
patients in the Netherlands, notwithstanding differences in
study design and methods [21]. We note that because
follow-up in our study was limited to the second cycle of
chemotherapy and did not extend through the end of the
chemotherapy course as in the study by Aarts et al., report-
ed FN incidence proportions should be interpreted accord-
ingly. We also note that caution should be exercised in
generalizing the results of our study since incidence pro-
portions, and FN odds with versus without pegfilgrastim
prophylaxis, may be different in later cycles.
While clinical practice guidelines recommend CSF pro-
phylaxis when FN risk is high (>20 %) based on either che-
motherapy regimen risk alone or a combination of regimen
risk and patient risk factors, recent publications have reported
widespread use of these agents in a manner that is inconsistent
with guidelines [1, 8]. For this reason, and because of the
relatively high cost of CSF agents, reducing the inappropriate
use of CSF prophylaxis has been targeted as one of the key
opportunities to reduce healthcare expenditures [30–33].
While the precise reasons for prophylaxis discontinuation in
our study are unknown, the use of abbreviated prophylactic
regimens should be carefully considered by providers, as the
results of this study (and those from Aarts et al.) suggest that
premature discontinuation could lead to additional FN events,
which may require hospitalization and may be associated with
severe consequences [2, 4, 21, 34–36].
We note a few limitations and possibilities for bias in the
current study. In clinical practice, patients who receive
pegfilgrastim prophylaxis in cycle 1 and cycle 2 may be sys-
tematically different than those who received it in cycle 1 only,
and to the extent such differences are unobserved, study re-
sults may be biased. For example, underlying FN risk in cycle
2 may be higher among those receiving prophylaxis in cycle 2
versus those not receiving it in cycle 2 due to differences in
absolute neutrophil count (ANC) and/or chemotherapy dose
(both of which are unobservable in the study repositories),
which would bias the study toward the null hypothesis (i.e.,
no difference in FN risk between groups).
Because there is no ICD-9-CM diagnosis code for FN,
codes for neutropenia, fever, and infection were employed to
identify inpatient and outpatient encounters that are assumed
to be related to FN. Since patients are typically not given
chemotherapy when they are neutropenic or have active infec-
tion, the appearance of codes for neutropenia, fever, or infec-
tion within a defined exposure period after receiving chemo-
therapy increases the likelihood that such outcomes are related
to receipt of chemotherapy. While the sensitivity of the broad
definition for FN used in this study is likely higher than that of
the narrow definition using only the ICD-9-CM code for neu-
tropenia, the specificity and positive predictive values are like-
ly lower, chiefly due to the inclusion of infections occurring in
Table 3 (continued)
FN-broad definitionb, inpatient+outpatient FN-narrow definitonc, inpatient+outpatient
n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value
PEG in cycles 1 and 2—matched (n=169) 7 (4.1) 3 (1.8)
All patients†
PEG in cycle 1 only (n=169) 11 (6.5) 2.1 (1.0–4.0) 0.019 5 (3.0) 2.0 (0.7–5.3) 0.171
PEG in cycles 1 and 2—all (n=4722) 152 (3.2) 72 (1.5)
Non-metastatic lung cancer-CAR+PAC
Matched patients
PEG in cycle 1 only (n=144) 6 (4.2) 1.0 (0.3–2.9) 1.000 2 (1.4) – –
PEG in cycles 1 and 2—matched (n=144) 6 (4.2) 0 (0.0)
All patients†
PEG in cycle 1 only (n=144) 6 (4.2) 1.6 (0.7–4.1) 0.299 2 (1.4) – –
PEG in cycles 1 and 2—all (n=1368) 39 (2.9) 2 (0.1)
OR odds ratio, CI confidence interval, PEG pegfilgrastim, TC docetaxel+cyclophosphamide, TAC docetaxel+doxorubicin+cyclophosphamide, TCH
docetaxel+carboplatin+trastuzumab, AC and AC-T doxorubicin+cyclophosphamide, with or without subsequent docetaxel or paclitaxel, FOLFOX
folinic aci+fluorouracil+oxaliplatin, CHOP cyclophosphamide+doxorubicin+vincristine+prednisone with rituximab (R), CAR+PAC carboplatin+
paclitaxel
a Odds ratios could not be estimated for subgroups in which number of events was small (n≤2)
b Hospital admission with diagnosis of neutropenia, infection, or fever, or outpatient encounter with such a diagnosis and IV antimicrobial therapy
cHospital admission with diagnosis of neutropenia or outpatient encounter with such diagnosis and IVantimicrobial therapy
†Odds ratios adjusted for potential confounders via multivariate regression
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the absence of fever and neutropenia [27]. Some infection-
related encounters during a given cycle may occur after che-
motherapy-induced neutropenia has resolved, especially
those that occur temporally later in the cycle (e.g., day 14
and later). In addition, because the study databases do not
include information on the use of drugs in hospital, iden-
tification of FN episodes requiring inpatient care was based
on diagnosis codes only. While the precise direction and
magnitude of these limitations/biases are unknown, there is
no reason to believe that they should disproportionately
impact comparison patients versus pegfilgrastim patients.
Because the accuracy of algorithms/variables capturing the
presence of acute and chronic conditions is undoubtedly less
than perfect and because histories are left-truncated, some pa-
tients may be misclassified in terms of their comorbidity pro-
file and/or prechemotherapy healthcare experience. Similarly,
the accuracy of our algorithms for identifying the primary
tumor type and presence of metastatic disease is unknown.
Because the study population comprised (principally) cancer
patients aged less than 65 years with coverage from private US
health plans, the study population may not reflect US patients
treated in clinical practice across the USA. Consequently,
study results may not be generalizable to those with public
health insurance, the uninsured, older patients, and patients
residing outside of the USA. Finally, our study was sponsored
by Amgen, a manufacturer of pegfilgrastim. We note, howev-
er, that our studywas undertaken in response to the publication
of findings from a randomized trial that was not sponsored by
Amgen or any other biopharma organization and that also
found prophylaxis discontinuation to be associated with a sig-
nificantly higher risk of FN [21, 37]. Notwithstanding these
corroborative findings, we believe that additional independent
research evaluating the relationship between prophylaxis dis-
continuation and FN risk is warranted.
In summary, in this retrospective evaluation of cancer che-
motherapy patients who received first-cycle pegfilgrastim pro-
phylaxis in US clinical practice, a clinically relevant minority
did not receive second-cycle prophylaxis. Second-cycle FN
odds among this subset were substantially higher than they
were among those who continued prophylaxis. Accordingly,
the decision to use abbreviated pegfilgrastim prophylaxis
schedules in clinical practice should be carefully considered
against the associated risks.
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